{"id":745698,"date":"2018-07-02T00:00:00","date_gmt":"2018-07-02T00:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-approved-in-japan-for-brca-mutated-metastatic-breast-cancer\/"},"modified":"2025-11-07T01:27:12","modified_gmt":"2025-11-07T06:27:12","slug":"lynparza-olaparib-approved-in-japan-for-brca-mutated-metastatic-breast-cancer","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-approved-in-japan-for-brca-mutated-metastatic-breast-cancer\/","title":{"rendered":"LYNPARZA\u00ae (olaparib) Approved in Japan for BRCA-Mutated Metastatic Breast Cancer"},"content":{"rendered":"<p class=\"bwalignc\">LYNPARZA is the First and Only PARP Inhibitor Approved for Use Beyond Ovarian Cancer<\/p>\n<p class=\"bwalignc\">Second Approval in Japan for AstraZeneca and Merck\u2019s LYNPARZA<\/p>\n<p>AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States<br \/>\n      and Canada, today announced that Japan\u2019s Pharmaceuticals and Medical<br \/>\n      Devices Agency (PMDA) has approved LYNPARZA<sup>\u00ae<\/sup> (olaparib)<br \/>\n      tablets for use in patients with unresectable or recurrent <i>BRCA<\/i>-mutated<br \/>\n      (<i>BRCA<\/i>m), human epidermal growth factor receptor 2 (HER2)-negative<br \/>\n      breast cancer who have received prior chemotherapy. Patients are<br \/>\n      selected for therapy based on an approved companion diagnostic.\n    <\/p>\n<p>\n      Dave Fredrickson, executive vice president, head of the oncology<br \/>\n      business unit at AstraZeneca, said, \u201cEarlier this year, LYNPARZA became<br \/>\n      the first PARP inhibitor available in Japan for advanced ovarian cancer.<br \/>\n      Now patients in Japan with <i>BRCA<\/i>-mutated, metastatic breast cancer<br \/>\n      will also have the opportunity to benefit from LYNPARZA. This latest<br \/>\n      approval underlines our ongoing efforts to make LYNPARZA available<br \/>\n      across multiple cancers as quickly as possible to patients around the<br \/>\n      world.\u201d\n    <\/p>\n<p>\n      Dr. Roy Baynes, senior vice president and head of global clinical<br \/>\n      development, chief medical officer, Merck Research Laboratories, said,<br \/>\n      \u201cMetastatic breast cancer is a complex disease with remaining unmet<br \/>\n      medical need. This approval is significant for breast cancer patients as<br \/>\n      the evaluation of <i>BRCA<\/i> mutations, in addition to hormone receptor<br \/>\n      and HER2 status, now becomes an important step in the management of the<br \/>\n      disease.\u201d\n    <\/p>\n<p>\n      The approval is based on data from the randomized, open-label, <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.nejm.org%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1706450&amp;esheet=51830097&amp;newsitemid=20180701005080&amp;lan=en-US&amp;anchor=Phase+3+OlympiAD+trial&amp;index=1&amp;md5=512cc8d393d559f5b6cfd0e165222513\" rel=\"nofollow\">Phase<br \/>\n      3 OlympiAD trial<\/a>, which tested LYNPARZA versus chemotherapy.<br \/>\n      Patients were selected for therapy based upon a confirmed <i>BRCA<\/i><br \/>\n      mutation. In the trial, LYNPARZA significantly prolonged<br \/>\n      progression-free survival (PFS) compared with chemotherapy, reducing the<br \/>\n      risk of disease progression or death by 42 percent (HR=0.58 [95% CI,<br \/>\n      0.43-0.80]; p=0.0009). Median PFS was 7.0 months with LYNPARZA versus<br \/>\n      4.2 months with chemotherapy.\n    <\/p>\n<p>\n      LYNPARZA was generally well tolerated, with the majority of adverse<br \/>\n      events (AEs) reported as mild to moderate with a lower rate of Grade \u22653<br \/>\n      AEs compared with chemotherapy (36.6% vs 50.5%). The most common AEs<br \/>\n      were nausea (50.2%), anemia (32.2%) and fatigue (22.4%).\n    <\/p>\n<p>\n      LYNPARZA is also approved in Japan as maintenance treatment for women<br \/>\n      with platinum-sensitive relapsed ovarian cancer, regardless of <i>BRCA<\/i><br \/>\n      mutation status. In Japan, the co-promotion of LYNPARZA by both<br \/>\n      companies began on July 1, 2018.\n    <\/p>\n<p>\n      <b>Important Safety Information<\/b>\n    <\/p>\n<p>\n      <b>Contraindications<\/b>\n    <\/p>\n<p>\n      There are no contraindications for LYNPARZA.\n    <\/p>\n<p>\n      <b>Warnings and Precautions<\/b>\n    <\/p>\n<p>\n      <b>Myelodysplastic Syndrome\/Acute Myeloid Leukemia (MDS\/AML): <\/b>Occurred<br \/>\n      in &lt;1.5% of patients exposed to LYNPARZA monotherapy, and the majority<br \/>\n      of events had a fatal outcome. The duration of therapy in patients who<br \/>\n      developed secondary MDS\/AML varied from &lt;6 months to &gt;2 years. All of<br \/>\n      these patients had previous chemotherapy with platinum agents and\/or<br \/>\n      other DNA-damaging agents, including radiotherapy, and some also had a<br \/>\n      history of more than one primary malignancy or of bone marrow dysplasia.\n    <\/p>\n<p>\n      Do not start LYNPARZA until patients have recovered from hematological<br \/>\n      toxicity caused by previous chemotherapy (\u2264Grade 1). Monitor complete<br \/>\n      blood count for cytopenia at baseline and monthly thereafter for<br \/>\n      clinically significant changes during treatment. For prolonged<br \/>\n      hematological toxicities, interrupt LYNPARZA and monitor blood count<br \/>\n      weekly until recovery.\n    <\/p>\n<p>\n      If the levels have not recovered to Grade 1 or less after 4 weeks, refer<br \/>\n      the patient to a hematologist for further investigations, including bone<br \/>\n      marrow analysis and blood sample for cytogenetics. Discontinue LYNPARZA<br \/>\n      if MDS\/AML is confirmed.\n    <\/p>\n<p>\n      <b>Pneumonitis: <\/b>Occurred in &lt;1% of patients exposed to LYNPARZA, and<br \/>\n      some cases were fatal. If patients present with new or worsening<br \/>\n      respiratory symptoms such as dyspnea, cough, and fever, or a<br \/>\n      radiological abnormality occurs, interrupt LYNPARZA treatment and<br \/>\n      initiate prompt investigation. Discontinue LYNPARZA if pneumonitis is<br \/>\n      confirmed and treat patient appropriately.\n    <\/p>\n<p>\n      <b>Embryo-Fetal Toxicity: <\/b>Based on its mechanism of action and<br \/>\n      findings in animals,\n    <\/p>\n<p>\n      LYNPARZA can cause fetal harm. A pregnancy test is recommended for<br \/>\n      females of reproductive potential prior to initiating treatment.\n    <\/p>\n<p>\n      <i>Females<\/i>\n    <\/p>\n<p>\n      Advise females of reproductive potential of the potential risk to a<br \/>\n      fetus and to use effective contraception during treatment and for 6<br \/>\n      months following the last dose.\n    <\/p>\n<p>\n      <i>Males<\/i>\n    <\/p>\n<p>\n      Advise male patients with female partners of reproductive potential or<br \/>\n      who are pregnant to use effective contraception during treatment and for<br \/>\n      3 months following the last dose of LYNPARZA and to not donate sperm<br \/>\n      during this time.\n    <\/p>\n<p>\n      <b>Adverse Reactions\u2014Maintenance Setting<\/b>\n    <\/p>\n<p>\n      Most common adverse reactions (Grades 1-4) in \u226520% of patients in<br \/>\n      clinical trials of LYNPARZA in the <b>maintenance setting <\/b>for <b>SOLO-2<\/b>:<br \/>\n      nausea (76%), fatigue (including asthenia) (66%), anemia (44%), vomiting<br \/>\n      (37%), nasopharyngitis\/upper respiratory tract infection (URI)\/influenza<br \/>\n      (36%), diarrhea (33%), arthralgia\/myalgia (30%), dysgeusia (27%),<br \/>\n      headache (26%), decreased appetite (22%), and stomatitis (20%).\n    <\/p>\n<p>\n      <b>Study 19: <\/b>nausea (71%), fatigue (including asthenia) (63%),<br \/>\n      vomiting (35%), diarrhea (28%), anemia (23%), respiratory tract<br \/>\n      infection (22%), constipation (22%), headache (21%), and decreased<br \/>\n      appetite (21%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in<br \/>\n      clinical trials of LYNPARZA in the <b>maintenance setting (SOLO-2\/Study<br \/>\n      19<\/b>) were: increase in mean corpuscular volume (89%\/82%), decrease in<br \/>\n      hemoglobin (83%\/82%), decrease in leukocytes (69%\/58%), decrease in<br \/>\n      lymphocytes (67%\/52%), decrease in absolute neutrophil count (51%\/47%),<br \/>\n      increase in serum creatinine (44%\/45%), and decrease in platelets<br \/>\n      (42%\/36%).\n    <\/p>\n<p>\n      <b>Adverse Reactions\u2014Advanced g<i>BRCA<\/i>m Ovarian Cancer<\/b>\n    <\/p>\n<p>\n      Most common adverse reactions (Grades 1-4) in \u226520% of patients in<br \/>\n      clinical trials of\n    <\/p>\n<p>\n      LYNPARZA for <b>advanced g<i>BRCA<\/i>m ovarian cancer after 3 or more<br \/>\n      lines of chemotherapy <\/b>(pooled from 6 studies) were: fatigue<br \/>\n      (including asthenia) (66%), nausea (64%), vomiting (43%), anemia (34%),<br \/>\n      diarrhea (31%), nasopharyngitis\/upper respiratory tract infection (URI)<br \/>\n      (26%), dyspepsia (25%), myalgia (22%), decreased appetite (22%), and<br \/>\n      arthralgia\/musculoskeletal pain (21%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in<br \/>\n      clinical trials of LYNPARZA for <b>advanced g<i>BRCA<\/i>m ovarian cancer <\/b>(pooled<br \/>\n      from 6 studies) were: decrease in hemoglobin (90%), increase in mean<br \/>\n      corpuscular volume (57%), decrease in lymphocytes (56%), increase in<br \/>\n      serum creatinine (30%), decrease in platelets (30%), and decrease in<br \/>\n      absolute neutrophil count (25%).\n    <\/p>\n<p>\n      <b>Adverse Reactions\u2014g<i>BRCA<\/i>m, HER2-Negative Breast Cancer<\/b>\n    <\/p>\n<p>\n      Most common adverse reactions (Grades 1-4) in \u226520% of patients in <b>OlympiAD<\/b><br \/>\n      were: nausea (58%), anemia (40%), fatigue (including asthenia) (37%),<br \/>\n      vomiting (30%), neutropenia (27%), respiratory tract infection (27%),<br \/>\n      leukopenia (25%), diarrhea (21%), and headache (20%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in <b>OlympiAD<br \/>\n      <\/b>were: decrease in hemoglobin (82%), decrease in lymphocytes (73%),<br \/>\n      decrease in leukocytes (71%), increase in mean corpuscular volume (71%),<br \/>\n      decrease in absolute neutrophil count (46%), and decrease in platelets<br \/>\n      (33%).\n    <\/p>\n<p>\n      <b>Drug Interactions<\/b>\n    <\/p>\n<p>\n      <b>Anticancer Agents: <\/b>Clinical studies of LYNPARZA in combination<br \/>\n      with other myelosuppressive anticancer agents, including DNA-damaging<br \/>\n      agents, indicate a potentiation and prolongation of myelosuppressive<br \/>\n      toxicity.\n    <\/p>\n<p>\n      <b>CYP3A Inhibitors: <\/b>Avoid concomitant use of strong or moderate<br \/>\n      CYP3A inhibitors. If a strong or moderate CYP3A inhibitor must be<br \/>\n      co-administered, reduce the dose of LYNPARZA. Advise patients to avoid<br \/>\n      grapefruit, grapefruit juice, Seville oranges, and Seville orange juice<br \/>\n      during LYNPARZA treatment.\n    <\/p>\n<p>\n      <b>CYP3A Inducers: <\/b>Avoid concomitant use of strong or moderate CYP3A<br \/>\n      inducers when using LYNPARZA. If a moderate inducer cannot be avoided,<br \/>\n      there is a potential for decreased efficacy of LYNPARZA.\n    <\/p>\n<p>\n      <b>Use In Specific Populations<\/b>\n    <\/p>\n<p>\n      <b>Lactation: <\/b>No data are available regarding the presence of<br \/>\n      olaparib in human milk, its effects on the breastfed infant or on milk<br \/>\n      production. Because of the potential for serious adverse reactions in<br \/>\n      the breastfed infant, advise a lactating woman not to breastfeed during<br \/>\n      treatment with LYNPARZA and for 1 month after receiving the final dose.\n    <\/p>\n<p>\n      <b>Pediatric Use: <\/b>The safety and efficacy of LYNPARZA have not been<br \/>\n      established in pediatric patients.\n    <\/p>\n<p>\n      <b>Hepatic Impairment: <\/b>No adjustment to the starting dose is<br \/>\n      required in patients with mild hepatic impairment (Child-Pugh<br \/>\n      classification A). There are no data in patients with moderate or severe<br \/>\n      hepatic impairment.\n    <\/p>\n<p>\n      <b>Renal Impairment: <\/b>No adjustment to the starting dose is necessary<br \/>\n      in patients with mild renal impairment (CLcr=51-80 mL\/min). In patients<br \/>\n      with moderate renal impairment (CLcr=31-50 mL\/min), reduce the dose to<br \/>\n      200 mg twice daily. There are no data in patients with severe renal<br \/>\n      impairment or end-stage renal disease (CLcr \u226430 mL\/min).\n    <\/p>\n<p>\n      <b>Indications<\/b>\n    <\/p>\n<p>\n      LYNPARZA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated:\n    <\/p>\n<p>\n      For the maintenance treatment of adult patients with recurrent<br \/>\n      epithelial ovarian, fallopian tube, or primary peritoneal cancer, who<br \/>\n      are in complete or partial response to platinum-based chemotherapy.\n    <\/p>\n<p>\n      For the treatment of adult patients with deleterious or suspected<br \/>\n      deleterious germline <i>BRCA-<\/i>mutated (g<i>BRCA<\/i>m) advanced<br \/>\n      ovarian cancer who have been treated with 3 or more prior lines of<br \/>\n      chemotherapy. Select patients for therapy based on an FDA-approved<br \/>\n      companion diagnostic for LYNPARZA.\n    <\/p>\n<p>\n      In patients with deleterious or suspected deleterious g<i>BRCA<\/i>m,<i> <\/i>human<br \/>\n      epidermal growth factor receptor 2 (HER2)-negative metastatic breast<br \/>\n      cancer who have previously been treated with chemotherapy in the<br \/>\n      neoadjuvant, adjuvant or metastatic setting. Patients with hormone<br \/>\n      receptor (HR)-positive breast cancer should have been treated with a<br \/>\n      prior endocrine therapy or be considered inappropriate for endocrine<br \/>\n      treatment. Select patients for therapy based on an FDA-approved<br \/>\n      companion diagnostic for LYNPARZA.\n    <\/p>\n<p>\n      <b>Please see complete <\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.azpicentral.com%2Flynparza_tb%2Fpi_lynparza_tb.pdf%23page%3D1&amp;esheet=51830097&amp;newsitemid=20180701005080&amp;lan=en-US&amp;anchor=Prescribing+Information&amp;index=2&amp;md5=701e8dfaa8dd45d79c7ae8cfc3ffecb9\" rel=\"nofollow\"><br \/>\n<b>Prescribing<br \/>\n      Information<\/b><br \/>\n<\/a><br \/>\n<b>, including Patient Information (Medication Guide).<\/b>\n    <\/p>\n<p>\n      <b>About OlympiAD<\/b>\n    <\/p>\n<p>\n      OlympiAD was a randomized, open-label, multi-center Phase 3 trial<br \/>\n      assessing the efficacy and safety of LYNPARZA tablets (300 mg twice<br \/>\n      daily) compared to physician\u2019s choice of chemotherapy (capecitabine,<br \/>\n      eribulin, or vinorelbine) in 302 patients with human epidermal growth<br \/>\n      factor receptor 2 (HER2)-negative metastatic breast cancer with germline <i>BRCA<\/i>1<br \/>\n      (g<i>BRCA<\/i>1) or <i>BRCA<\/i>2<i> <\/i>(g<i>BRCA<\/i>2) mutations, which<br \/>\n      are confirmed or suspected to be deleterious. The international trial<br \/>\n      was conducted in 19 countries across Europe, Asia, North America and<br \/>\n      South America.\n    <\/p>\n<p>\n      Patients in the OlympiAD trial had HER2-negative g<i>BRCA<\/i>1- or g<i>BRCA<\/i>2-mutated<br \/>\n      breast cancer, which was hormone receptor positive (HR+) or triple<br \/>\n      negative, and received LYNPARZA for metastatic disease. Approximately<br \/>\n      half of the patients in the LYNPARZA and chemotherapy arm of the trial<br \/>\n      were HR+ (n=152) and approximately half were triple negative (n=150).<br \/>\n      Among the 205 patients treated with LYNPARZA, the median age was 44<br \/>\n      years (range, 22 to 76). Before enrollment, patients had prior treatment<br \/>\n      with an anthracycline (unless contraindicated) and a taxane chemotherapy<br \/>\n      either in the neoadjuvant, adjuvant or metastatic setting, and no more<br \/>\n      than two prior lines of chemotherapy for metastatic disease. HR+<br \/>\n      patients had received at least one endocrine medicine or were not<br \/>\n      eligible for endocrine medicines. Prior treatments with endocrine<br \/>\n      medicines were not counted as prior lines of chemotherapy.\n    <\/p>\n<p>\n      The primary endpoint of the trial was progression-free survival (PFS) as<br \/>\n      measured by a Blinded Independent Central Review. Secondary endpoints<br \/>\n      included overall survival (OS), time to second progression or death<br \/>\n      (PFS2), objective response rate (ORR) and effect on health-related<br \/>\n      quality of life.\n    <\/p>\n<p>\n      <b>About <i>BRCA<\/i> Mutations<\/b>\n    <\/p>\n<p>\n      <i>BRCA<\/i>1 and <i>BRCA<\/i>2 are human genes that produce proteins<br \/>\n      responsible for repairing damaged DNA and play an important role in<br \/>\n      maintaining the genetic stability of cells. When either of these genes<br \/>\n      is mutated, or altered, such that its protein product either is not made<br \/>\n      or does not function correctly, DNA damage may not be repaired properly<br \/>\n      and cells become unstable. As a result, cells are more likely to develop<br \/>\n      additional genetic alterations that can lead to cancer.\n    <\/p>\n<p>\n      <b>About Breast Cancer in Japan<\/b>\n    <\/p>\n<p>\n      In Japan, breast cancer is the fifth leading cause of death among women.<br \/>\n      In Japanese women, breast cancer incidence peaks in the late forties,<br \/>\n      whereas in the U.S. and Europe, the peak incidence is in women over 60<br \/>\n      years of age. Despite more treatment options becoming available during<br \/>\n      the past three decades, there is currently no cure for patients<br \/>\n      diagnosed with metastatic (Stage 4) breast cancer. In Japan, five- and<br \/>\n      10-year relative survival rates for patients with Stage 4 breast cancer<br \/>\n      are as low as 32.6 percent and 15.6 percent, respectively. Therefore,<br \/>\n      the primary aim of treatment is to slow progression of the disease for<br \/>\n      as long as possible and improve or maintain a patient\u2019s quality of life.\n    <\/p>\n<p>\n      <b>About LYNPARZA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (olaparib) 100 mg tablets<\/b>\n    <\/p>\n<p>\n      LYNPARZA<i> <\/i>is the first-in-class PARP inhibitor and the first<br \/>\n      targeted treatment to potentially exploit DNA damage response (DDR)<br \/>\n      pathway deficiencies, such as <i>BRCA<\/i> mutations, to preferentially<br \/>\n      kill cancer cells. Specifically, <i>in vitro<\/i> studies have shown that<br \/>\n      LYNPARZA-induced cytotoxicity may involve inhibition of PARP enzymatic<br \/>\n      activity and increased formation of PARP-DNA complexes, resulting in DNA<br \/>\n      damage and cancer cell death. LYNPARZA is being tested in a range of<br \/>\n      DDR-deficient tumor types.\n    <\/p>\n<p>\n      LYNPARZA, which is being jointly developed and commercialized by<br \/>\n      AstraZeneca and Merck, is approved for advanced ovarian cancer and<br \/>\n      metastatic breast cancer and has been used in over 20,000 patients<br \/>\n      worldwide. LYNPARZA<i> <\/i>has a broad and advanced clinical trial<br \/>\n      development program and AstraZeneca and Merck are working together to<br \/>\n      deliver it as quickly as possible to more patients across multiple<br \/>\n      cancer types.\n    <\/p>\n<p>\n      <b>About the AstraZeneca and Merck Strategic Oncology Collaboration<\/b>\n    <\/p>\n<p>\n      In July 2017, AstraZeneca and Merck, known as MSD outside the United<br \/>\n      States and Canada, announced a global strategic oncology collaboration<br \/>\n      to co-develop and co-commercialize LYNPARZA, the world\u2019s first PARP<br \/>\n      inhibitor, and potential new medicine selumetinib, a MEK inhibitor, for<br \/>\n      multiple cancer types. Working together, the companies will develop<br \/>\n      LYNPARZA and selumetinib in combination with other potential new<br \/>\n      medicines and as monotherapies. Independently, the companies will<br \/>\n      develop LYNPARZA and selumetinib in combination with their respective<br \/>\n      PD-L1 and PD-1 medicines.\n    <\/p>\n<p>\n      <b>Merck\u2019s Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck, the potential<br \/>\n      to bring new hope to people with cancer drives our purpose and<br \/>\n      supporting accessibility to our cancer medicines is our commitment.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the largest development<br \/>\n      programs in the industry across more than 30 tumor types. We also<br \/>\n      continue to strengthen our portfolio through strategic acquisitions and<br \/>\n      are prioritizing the development of several promising oncology<br \/>\n      candidates with the potential to improve the treatment of advanced<br \/>\n      cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51830097&amp;newsitemid=20180701005080&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=3&amp;md5=c68a8b3c1d51fc0e5c67fb28f390df2a\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Findex.html&amp;esheet=51830097&amp;newsitemid=20180701005080&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=4&amp;md5=dfc75f65e576174b77557695baa3243b\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and&nbsp;connect with us on&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51830097&amp;newsitemid=20180701005080&amp;lan=en-US&amp;anchor=Twitter&amp;index=5&amp;md5=8c9fb2be8758bd471596df551c335a67\" rel=\"nofollow\">Twitter<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=51830097&amp;newsitemid=20180701005080&amp;lan=en-US&amp;anchor=Facebook&amp;index=6&amp;md5=a680119bc5d879802113b325a21bf499\" rel=\"nofollow\">Facebook<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=51830097&amp;newsitemid=20180701005080&amp;lan=en-US&amp;anchor=Instagram&amp;index=7&amp;md5=656090edbb4048deb4250b982efe69d2\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51830097&amp;newsitemid=20180701005080&amp;lan=en-US&amp;anchor=YouTube&amp;index=8&amp;md5=8970c0379fc1c43ec5ad449ac9256960\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51830097&amp;newsitemid=20180701005080&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=9&amp;md5=44229f1ad30c41aec12164ce62e70795\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2017 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51830097&amp;newsitemid=20180701005080&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=10&amp;md5=ea31b2dff8740ca163ebac140cf562b7\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20180701005080r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>Michael Close,        267-305-1211<br \/>or<br \/>Investors:<br \/>Teri Loxam, 908-740-1986<br \/>Michael        DeCarbo, 908-740-1807     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>LYNPARZA is the First and Only PARP Inhibitor Approved for Use Beyond Ovarian Cancer Second Approval in Japan for AstraZeneca and Merck\u2019s LYNPARZA AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that Japan\u2019s Pharmaceuticals and Medical Devices Agency (PMDA) has approved LYNPARZA \u00ae (olaparib) tablets for use in patients with unresectable or recurrent BRCA -mutated ( BRCA m), human epidermal growth factor receptor 2 (HER2)-negative breast cancer who have received prior chemotherapy. Patients are selected for therapy based on an approved companion diagnostic. Dave Fredrickson, executive vice president, head of the oncology business unit at AstraZeneca, said, \u201cEarlier this year, LYNPARZA became the first PARP inhibitor available in Japan for advanced ovarian cancer. Now patients in Japan with BRCA-mutated, metastatic breast cancer will also have the opportunity to benefit from LYNPARZA. This latest approval underlines our ongoing<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,289,56],"class_list":["post-745698","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>LYNPARZA\u00ae (olaparib) Approved in Japan for BRCA-Mutated Metastatic Breast Cancer - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-approved-in-japan-for-brca-mutated-metastatic-breast-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LYNPARZA\u00ae (olaparib) Approved in Japan for BRCA-Mutated Metastatic Breast Cancer - Merck.com\" \/>\n<meta property=\"og:description\" content=\"LYNPARZA is the First and Only PARP Inhibitor Approved for Use Beyond Ovarian Cancer Second Approval in Japan for AstraZeneca and Merck\u2019s LYNPARZA AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that Japan\u2019s Pharmaceuticals and Medical Devices Agency (PMDA) has approved LYNPARZA \u00ae (olaparib) tablets for use in patients with unresectable or recurrent BRCA -mutated ( BRCA m), human epidermal growth factor receptor 2 (HER2)-negative breast cancer who have received prior chemotherapy. Patients are selected for therapy based on an approved companion diagnostic. Dave Fredrickson, executive vice president, head of the oncology business unit at AstraZeneca, said, \u201cEarlier this year, LYNPARZA became the first PARP inhibitor available in Japan for advanced ovarian cancer. Now patients in Japan with BRCA-mutated, metastatic breast cancer will also have the opportunity to benefit from LYNPARZA. This latest approval underlines our ongoing\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-approved-in-japan-for-brca-mutated-metastatic-breast-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:27:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"13 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lynparza-olaparib-approved-in-japan-for-brca-mutated-metastatic-breast-cancer\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lynparza-olaparib-approved-in-japan-for-brca-mutated-metastatic-breast-cancer\\\/\",\"name\":\"LYNPARZA\u00ae (olaparib) Approved in Japan for BRCA-Mutated Metastatic Breast Cancer - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2018-07-02T00:00:00+00:00\",\"dateModified\":\"2025-11-07T06:27:12+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lynparza-olaparib-approved-in-japan-for-brca-mutated-metastatic-breast-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lynparza-olaparib-approved-in-japan-for-brca-mutated-metastatic-breast-cancer\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lynparza-olaparib-approved-in-japan-for-brca-mutated-metastatic-breast-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LYNPARZA\u00ae (olaparib) Approved in Japan for BRCA-Mutated Metastatic Breast Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LYNPARZA\u00ae (olaparib) Approved in Japan for BRCA-Mutated Metastatic Breast Cancer - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-approved-in-japan-for-brca-mutated-metastatic-breast-cancer\/","og_locale":"en_US","og_type":"article","og_title":"LYNPARZA\u00ae (olaparib) Approved in Japan for BRCA-Mutated Metastatic Breast Cancer - Merck.com","og_description":"LYNPARZA is the First and Only PARP Inhibitor Approved for Use Beyond Ovarian Cancer Second Approval in Japan for AstraZeneca and Merck\u2019s LYNPARZA AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that Japan\u2019s Pharmaceuticals and Medical Devices Agency (PMDA) has approved LYNPARZA \u00ae (olaparib) tablets for use in patients with unresectable or recurrent BRCA -mutated ( BRCA m), human epidermal growth factor receptor 2 (HER2)-negative breast cancer who have received prior chemotherapy. Patients are selected for therapy based on an approved companion diagnostic. Dave Fredrickson, executive vice president, head of the oncology business unit at AstraZeneca, said, \u201cEarlier this year, LYNPARZA became the first PARP inhibitor available in Japan for advanced ovarian cancer. Now patients in Japan with BRCA-mutated, metastatic breast cancer will also have the opportunity to benefit from LYNPARZA. This latest approval underlines our ongoing","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-approved-in-japan-for-brca-mutated-metastatic-breast-cancer\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:27:12+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-approved-in-japan-for-brca-mutated-metastatic-breast-cancer\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-approved-in-japan-for-brca-mutated-metastatic-breast-cancer\/","name":"LYNPARZA\u00ae (olaparib) Approved in Japan for BRCA-Mutated Metastatic Breast Cancer - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2018-07-02T00:00:00+00:00","dateModified":"2025-11-07T06:27:12+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-approved-in-japan-for-brca-mutated-metastatic-breast-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-approved-in-japan-for-brca-mutated-metastatic-breast-cancer\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-approved-in-japan-for-brca-mutated-metastatic-breast-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"LYNPARZA\u00ae (olaparib) Approved in Japan for BRCA-Mutated Metastatic Breast Cancer"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"d111f3e1-a64c-426a-9146-428cb688db4d","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/LYNPARZA-olaparib-Approved-in-Japan-for-BRCA-Mutated-Metastatic-Breast-Cancer-2018.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745698","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745698\/revisions"}],"predecessor-version":[{"id":3675041,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745698\/revisions\/3675041"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745698"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745698"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}